SFB 1074: Experimental Models and Clinical Translation in Leukemia

近年来，随着分子疗法的成功临床发展，在白血病发生的遗传驱动因素特征方面取得了巨大进展。合作研究中心（CRC） 1074从一开始就预测并伴随着这一发展。CRC 1074旨在弥合白血病领域的基础，转化和（预）临床研究，重点是将急性髓性白血病（AML），急性淋巴细胞白血病（ALL）和慢性淋巴细胞白血病（CLL）的发病机制转化为新疗法。CRC 1074的结构由两个密切互动的项目组组成：A组项目具有白血病发生实验模型的专业知识，B组项目专注于转化/临床前白血病研究。在这里，CRC 1074有幸受益于最明显的白血病临床研究和位于乌尔姆大学的国家白血病研究小组的独特生物库，属于世界上最大的临床和分子注释集合。单个项目由两个核心项目补充，生物信息学/单细胞测序核心（Z1）和质谱和蛋白质组学核心（Z3）。在拨款更新提案中，7名新的首席研究员被纳入其中，其中5名是年轻的女科学家，她们在职业生涯的不同阶段有着出色的记录。此外，CRC 1074结合了海德堡德国癌症研究中心的两个研究小组和柏林慈善大学医学院的一个研究小组，基于他们的专业知识和已经长期合作的基础上。我们期待CRC 1074的第三个资助期将进一步成功地加强乌尔姆大学基础和转化白血病研究的国际知名度，并继续提供重大的科学贡献。CRC 1074的宝贵资源将有助于将研究成果转化为临床实践，并最终改善白血病患者的护理。

In recent years, there has been enormous progress in characterizing genetic drivers in leukemogenesis, followed by the successful clinical development of molecular therapies. Collaborative Research Center (CRC) 1074 has anticipated and accompanied this development from the very beginning. CRC 1074 has aimed at bridging basic, translational and (pre)clinical research in the field of leukemia, focusing on translating insights into the pathogenesis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) into new therapies.The structure of CRC 1074 consists of two closely interacting Project Groups: Group A projects with the expertise in experimental models of leukemogenesis, and Group B projects focusing on translational / preclinical leukemia research. Here, CRC 1074 has the privilege to benefit from most visible clinical research in leukemia and unique biobanks of the national leukemia study groups located at Ulm University, belonging to the largest clinically and molecularly annotated collections worldwide. The individual projects are complemented by two core projects, the Bioinformatics/Single-Cell Sequencing Core (Z1) and the Mass Spectrometry and Proteomics Core (Z3). In the grant renewal proposal, seven new principal investigators have been integrated, five of them being young female scientists with an outstanding record, at different stages of their career. Furthermore, CRC 1074 has integrated two research groups from the German Cancer Research Center in Heidelberg, and one group from Charité University Medicine Berlin, based on their specific expertise and on already long-standing collaborations.We expect that a third funding period of CRC 1074 will further successfully strengthen the international visibility of basic and translational leukemia research at Ulm University and continue to provide major scientific contributions. The invaluable resources of CRC 1074 will facilitate translating research findings into clinical practice and ultimately improve care of patients with leukemia.